Intellia's near-term outlook hinges on the clinical execution of its lead programs, NTLA-2001 and NTLA-2002, as the company's cash position of $106.1M and TTM operating loss of ~$400M suggest a runway of less than one year without additional financing.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.91-14.2% vs -$0.80 | $7M-26.5% vs $10M |
Q3 2026 Aug 6, 2026 | -$0.80-0.1% vs -$0.80 | $8M-41.0% vs $13M |
Q2 2026 May 11, 2026 | -$0.81+12.0% vs -$0.92 | $15M+9.0% vs $14M |
Q1 2026 Feb 26, 2026 | -$0.83+16.2% vs -$0.99 | $23M+92.1% vs $12M |
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on November 1, 2026, it awarded inducement grants to three new employees as a material inducement to employment.
Intellia Therapeutics approaches a pivotal FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy for hereditary angioedema. Lonvo-z's Phase 3 data showed ~87% attack reduction and a clean safety profile, positioning NTLA as a transformative one-time treatment in a crowded, high-cost market. Commercial success hinges on payer acceptance, physician adoption, and pricing strategy, with initial revenues likely modest but long-term potential significant if approved.
NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.92 per share a year ago.
Benchmark NTLA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Intellia Therapeutics, Inc. (NTLA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $2.57 | $394.4M | -4.15 | 25.39% | -157.32% | -196.63% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $2.38 | $259.88M | -15.80 | — | — | -5.76% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — |
Intellia Therapeutics, Inc. (NTLA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Intellia Therapeutics, Inc. (NTLA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 15, 2026·SEC
Jun 10, 2026·SEC
Get notified when NTLA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Intellia Therapeutics, Inc. (NTLA) stock FAQ — growth, dividends, profitability & financials explained
Intellia Therapeutics, Inc. (NTLA) reported $52.9M in revenue over the trailing twelve months. Revenue was $67.7M in fiscal year 2025.
Intellia Therapeutics, Inc. (NTLA) revenue fell by 8.1% over the trailing twelve months, compared with the twelve months before.
No. Intellia Therapeutics, Inc. (NTLA) reported a net loss of $426.1M over the trailing twelve months.
Intellia Therapeutics, Inc. (NTLA) had a return on equity (ROE) of -64.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Intellia Therapeutics, Inc. (NTLA) had negative free cash flow of $358.1M over the trailing twelve months.
